Fibroblast growth factors (FGFs) are a family of proteins involved in critical biological processes, including cell proliferation, differentiation, migration, and tissue repair. Their role in supporting and treating injuries, particularly those involving skin, nerve, and bone tissues, is supported by a significant body of scientific research. Numerous preclinical studies and some clinical trials have demonstrated that FGFs, especially basic FGF (bFGF or FGF-2), can stimulate wound healing by promoting angiogenesis (the formation of new blood vessels), collagen deposition, and the proliferation of fibroblasts and other repair cells at the injury site.

Topical application of recombinant human bFGF has been studied in the treatment of chronic wounds, burns, and skin ulcers, with reports of enhanced healing rates and improved tissue regeneration compared to standard care. FGFs are also being explored for their potential in nerve regeneration and bone repair, with promising results in animal models. However, while the preclinical and early clinical evidence is robust, larger and more definitive clinical trials are needed to establish standardized protocols and to fully assess long-term safety and efficacy.

In summary, the use of FGFs to support injury healing is justified by scientific evidence, with a moderate to strong level of support (4/5), particularly in the context of skin and soft tissue repair. Their use is increasingly being developed in clinical settings, though further research is warranted.